The third phase of clinical trials for Sputnik V for people over 60 years old has finished showing a high level of safety and efficacy.
This is according to Russian Health Minister, Mikhail Murashko on Thursday, local time.
He added, the vaccine's developer Gamaleya Center, is now updating its recommendations for use and is compiling a final report on the test results.
Funded by the Russian Direct Investment Fund this viral vector vaccine was the first COVID-19 vaccine to be developed in the world in August last year.
It was rolled out following phase 2 trials prompting concerns over its safety when it first was administered to citizens.
However, the Lancet backed the vaccine last February based on phase 3 results available at the time, easing some concerns.
At the moment more than 70 countries have rolled out the vaccine to its citizens.